Antibody Based Therapeutics
Showing 1 - 25 of >10,000
B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)
Active, not recruiting
- B-Cell Lymphoma
- TG-1801
- Ublituximab
-
Heidelberg, Victoria, Australia
- +2 more
Jan 20, 2023
Assess New Participant's Perspectives Beyond Clinical Efficacy
Not yet recruiting
- Multiple Sclerosis, Relapsing-Remitting
- (no location specified)
Nov 7, 2023
Locally Advanced Unresectable or Metastatic Esophageal Cancer Trial (Futibatinib, Pembrolizumab, Cisplatin)
Not yet recruiting
- Locally Advanced Unresectable or Metastatic Esophageal Cancer
- Futibatinib
- +6 more
- (no location specified)
Jul 6, 2023
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
Chronic Kidney Disease(CKD), Uncontrolled Hypertension Trial in Tours (Antihypertensive algorithm, Standard of care)
Not yet recruiting
- Chronic Kidney Disease(CKD)
- Uncontrolled Hypertension
- Antihypertensive algorithm
- Standard of care
-
Tours, FranceDepartment of Nephrology, University Hospital of Tours
Feb 8, 2023
Intermittent Exotropia Trial in Goyang, Seoul (Nu.T, No-Treatment Control)
Not yet recruiting
- Intermittent Exotropia
- Nu.T
- No-Treatment Control
-
Goyang, Korea, Republic of
- +3 more
Nov 3, 2023
Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)
Recruiting
- Recurrent Osteosarcoma
- humanized anti-GD2 antibody
- GM-CSF
-
Los Angeles, California
- +2 more
Dec 22, 2022
Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)
Recruiting
- Locally Advanced
- Non-small Cell Lung Cancer
- Serplulimab
- +5 more
-
Shanghai, ChinaShanghai Pulmonary Hospital
Mar 14, 2023
ABO Blood Type Incompatible Kidney Transplantation, Antibody-mediated Rejection Trial in Seoul (5-gene classification model)
Active, not recruiting
- ABO Blood Type Incompatible Kidney Transplantation
- Antibody-mediated Rejection
- 5-gene classification model
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)
Recruiting
- Non Small Cell Lung Cancer
- Lung Cancer
- FLT3 Ligand (CDX-301)
- +2 more
-
Bronx, New YorkAlbert Einstein College of Medicine
Jul 18, 2022
NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)
Terminated
- Non-small Cell Lung Cancer
- REGN2810/ipi
- +2 more
-
Saint Petersburg, Florida
- +2 more
Oct 22, 2022
Rational Therapeutics Based on Matched Tumor and Normal Tissue
Completed
- Advanced Cancers
- Treatment Based on Genetic Mutation
- Treatment Based on No Genetic Mutation
-
Houston, Texas
- +3 more
Feb 11, 2022
Amphetamine-Related Disorders Trial (Mobile-app based contingency management)
Not yet recruiting
- Amphetamine-Related Disorders
- Mobile-app based contingency management
- (no location specified)
Aug 23, 2022
Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)
Recruiting
- Multiple Myeloma in Relapse
- Selinexor
- +4 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 31, 2023
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis Trial in Chongqing
Recruiting
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- ANCA-Associated Glomerulonephritis
-
Chongqing, Chongqing, ChinaChildren's Hospital of Chongqing Medical University
Jul 23, 2023
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1
Completed
- Recurrent Cervical Carcinoma
- +4 more
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,
Not yet recruiting
- Idiopathic Inflammatory Myopathies
- +3 more
- KYV-101
- +2 more
- (no location specified)
Nov 21, 2023
Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)
Active, not recruiting
- Neuroblastoma
- Hu3F8 With GM-CSF
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 2, 2022
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in San Francisco (drug, biological, procedure)
Recruiting
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- 89Zr-DFO-YS5
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 29, 2022
SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease Trial in Bangkok (Human IgG1 anti-SARS-CoV-2 antibody cocktail,
Completed
- SARS CoV 2 Infection
- SARS-CoV-2 Acute Respiratory Disease
- Human IgG1 anti-SARS-CoV-2 antibody cocktail
- Placebo
-
Bangkok, ThailandNational Cancer Institute of Thailand
Jul 5, 2022
Influenza Vaccination Trial in Singapore (Flublok Quadrivalent vaccine, Fluarix Quadrivalent vaccine, Flucelvax Quadrivalent
Not yet recruiting
- Influenza Vaccination
- Flublok Quadrivalent vaccine
- +2 more
-
Singapore, SingaporeNational Centre for Infectious Diseases (NCID)
Jul 26, 2022
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,
Terminated
- Non-Hodgkins Lymphoma
- +6 more
-
Huntsville, Alabama
- +1 more
May 5, 2022
